DarioHealth Corp. (DRIO) director buys 14,430 shares at $6.93
Rhea-AI Filing Summary
DarioHealth Corp. director Dennis Matheis purchased 14,430 shares of Common Stock at $6.93 per share on July 23, 2026, under a Securities Purchase Agreement dated July 22, 2026. Earlier, on August 12, 2024, 50 shares of his Series B-2 Preferred Stock automatically converted into 965 post–reverse-split common shares, subject to a 19.99% beneficial ownership blocker, and he beneficially owned 28,596 common shares immediately after that conversion.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 15,395 shares
Net Buy
3 txns
Insider
Matheis Dennis
Role
Director
Bought
14,430 shs ($100K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F3 | 14,430 | $6.93 | $100K |
| Conversion | Series B-2 Preferred Stock | 50 | $1,000.00 | $50K |
| Conversion | Common Stock F1, F2 | 965 | $19.10 | $18K |
Holdings After Transaction:
Series B-2 Preferred Stock — 0 shares (Direct);
Common Stock — 43,026 shares (Direct)
Footnotes (3)
- F1. Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.
- F2. The Reporting Person's 50 shares of Series B-2 Preferred Stock automatically converted into 19,289 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 965 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 28,596 shares of Common Stock immediately following the conversion.
- F3. The reported shares were acquired pursuant to a Securities Purchase Agreement with the issuer, dated July 22, 2026, at a purchase price of $6.93 per share.
Key Figures
Common shares purchased: 14,430 shares
Purchase price: $6.93 per share
Preferred shares converted: 50 shares
+4 more
7 metrics
Common shares purchased
14,430 shares
Common Stock bought by director Dennis Matheis on July 23, 2026
Purchase price
$6.93 per share
Price under Securities Purchase Agreement dated July 22, 2026
Preferred shares converted
50 shares
Series B-2 Preferred Stock automatically converted on August 12, 2024
Common shares from conversion
965 shares
Common Stock reported after reverse stock split from conversion of 50 Series B-2 Preferred shares
Beneficial ownership after conversion
28,596 shares
Common Stock beneficially owned by Dennis Matheis immediately following August 12, 2024 conversion
Ownership blocker
19.99%
Non-waivable beneficial ownership limitation on automatic conversion of Series B Preferred Stock
Series B-2 conversion price
$1,000.00 per share
Conversion price for Series B-2 Preferred Stock
Key Terms
Series B-2 Preferred Stock, reverse stock split, beneficial ownership limitations, Securities Purchase Agreement
4 terms
Series B-2 Preferred Stock financial
"The Reporting Person's 50 shares of Series B-2 Preferred Stock automatically converted"
reverse stock split financial
"Following the Issuer's subsequent reverse stock split, the conversion shares are reported"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
beneficial ownership limitations financial
"subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
Securities Purchase Agreement financial
"acquired pursuant to a Securities Purchase Agreement with the issuer, dated July 22, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Dennis Matheis report for DarioHealth Corp. (DRIO) on July 23, 2026?
On July 23, 2026, director Dennis Matheis reported purchasing 14,430 shares of DarioHealth Common Stock. The shares were bought at $6.93 per share under a Securities Purchase Agreement dated July 22, 2026, and are held as a direct ownership position.
What was the nature of Dennis Matheis’s August 12, 2024 preferred stock conversion in DarioHealth (DRIO)?
On August 12, 2024, 50 shares of his Series B-2 Preferred Stock automatically converted into DarioHealth common stock. After a subsequent reverse stock split, the conversion is reported as 965 common shares, and he also received common shares under the preferred stock’s dividend provisions.
What beneficial ownership limitation applied to DarioHealth (DRIO) Series B Preferred Stock?
The Series B Preferred Stock carried beneficial ownership limitations, including a non-waivable 19.99% ownership blocker. Automatic conversion into common stock occurred on the 15‑month anniversary of issuance, but remained subject to this ownership cap to limit the holder’s percentage stake.
Was Dennis Matheis’s July 2026 DarioHealth (DRIO) purchase under a Rule 10b5-1 trading plan?
The report indicates the July 23, 2026 purchase of 14,430 shares at $6.93 per share was not effected pursuant to a Rule 10b5-1 trading plan. The associated Rule 10b5-1 checkbox for the filing was explicitly left unchecked.